What happened
Biotech giant CSL reported a full-year loss driven by a US$7.1 billion asset impairment. Despite the headline net loss, the company kept its dividend intact and issued FY27 earnings guidance that exceeded consensus market expectations. CSL shares rallied on the ASX following the update, helping drive an 8% gain across the domestic healthcare sector.
Why it matters here
Healthcare has been one of the most underperforming sectors on the Australian share market this year, leading to depressed valuations for major blue-chip holdings. CSL's ability to maintain its dividend payout while projecting stronger forward underlying profit provides reassurance to income and growth portfolios that the worst of the operational earnings downgrades may now be in the rearview mirror.
What to watch
Track CSL's upcoming ex-dividend date on 9 September 2026, the final dividend payment on 2 October 2026, and its Annual General Meeting scheduled for 27 October 2026.
Source
marketindex.com.au